

=> d his

(FILE 'HOME' ENTERED AT 15:31:05 ON 18 JUL 2002)

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 15:31:27 ON 18 JUL 2002

SEA (CS4 OR (COLI (A) SURFACE (A) ANTIGEN) OR PILIN) AND (ETEC

-----  
6 FILE ADISALERTS  
1 FILE ADISINSIGHT  
1 FILE ADISNEWS  
9 FILE AGRICOLA  
1 FILE AQUASCI  
2 FILE BIOBUSINESS  
2 FILE BIOCOMMERCE  
327 FILE BIOSIS  
35 FILE BIOTECHABS  
35 FILE BIOTECHDS  
246 FILE BIOTECHNO  
19 FILE CABA  
14 FILE CANCERLIT  
728 FILE CAPLUS  
3 FILE CEABA-VTB  
3 FILE CONFSCI  
3 FILE DDFU  
246 FILE DGENE  
1 FILE DRUGNL  
11 FILE DRUGU  
1 FILE DRUGUPDATES  
2 FILE EMBAL  
275 FILE EMBASE  
118 FILE ESBIODBASE  
5 FILE FEDRIP  
42 FILE FSTA  
170 FILE GENBANK  
13 FILE IFIPAT  
3 FILE JICST-EPLUS  
220 FILE LIFESCI  
364 FILE MEDLINE  
117 FILE PASCAL  
1 FILE PHAR  
1 FILE PHIN  
7 FILE PROMT  
383 FILE SCISEARCH  
229 FILE TOXCENTER  
226 FILE USPATFULL  
1 FILE USPAT2  
20 FILE WPIDS  
20 FILE WPINDEX  
1 FILE CBNB  
9 FILE NLDB

L1 QUE (CS4 OR (COLI (A) SURFACE (A) ANTIGEN) OR PILIN) AND (ETEC

-----  
SEA L1 AND (VACCINE OR IMMUNOGEN)

-----  
6 FILE ADISALERTS  
1 FILE ADISINSIGHT

1 FILE ADISNEWS  
 1 FILE AQUASCI  
 1 FILE BIOCOMMERCE  
 39 FILE BIOSIS  
 24 FILE BIOTECHABS  
 24 FILE BIOTECHDS  
 22 FILE BIOTECHNO  
 2 FILE CABA  
 2 FILE CANCERLIT  
 138 FILE CAPLUS  
 1 FILE CEABA-VTB  
 3 FILE DDFU  
 174 FILE DGENE  
 1 FILE DRUGNL  
 10 FILE DRUGU  
 1 FILE DRUGUPDATES  
 28 FILE EMBASE  
 17 FILE ESBIODBASE  
 1 FILE FEDRIP  
 3 FILE FSTA  
 1 FILE GENBANK  
 6 FILE IFIPAT  
 21 FILE LIFESCI  
 39 FILE MEDLINE  
 15 FILE PASCAL  
 1 FILE PHAR  
 6 FILE PROMT  
 34 FILE SCISEARCH  
 30 FILE TOXCENTER  
 166 FILE USPATFULL  
 1 FILE USPAT2  
 16 FILE WPIDS  
 16 FILE WPINDEX  
 1 FILE CBNB  
 0\* FILE USAN  
 9 FILE NLDB

FILE 'CAPLUS, SCISEARCH, MEDLINE, BIOSIS, EMBASE, BIOTECHNO, DGENE,  
 TOXCENTER, LIFESCI, GENBANK' ENTERED AT 15:44:43 ON 18 JUL 2002

L2 3188 S (CS4 OR (COLI (A) SURFACE (A) ANTIGEN) OR PILIN) AND (ETEC OR  
 L3 526 S L1 AND (VACCINE OR IMMUNOGEN)  
 L4 351 DUPLICATE REMOVE L3 (175 DUPLICATES REMOVED)  
 L5 78 S L4 AND SUBUNIT  
 L6 551 S (CS4 OR (COLI (A) SURFACE (A) ANTIGEN) OR PILIN) AND ETEC  
 L7 185 S L6 AND (VACCINE OR IMMUNOGEN)  
 L8 100 S L6 AND CS4 (P) (VACCINE OR IMMUNOGEN)  
 L9 44 DUPLICATE REMOVE L8 (56 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 15:55:54 ON 18 JUL 2002

L9 ANSWER 10 OF 44 SCISEARCH COPYRIGHT 2002 ISI (R) DUPLICATE 6  
AN 1998:178598 SCISEARCH  
GA The Genuine Article (R) Number: YY555  
TI Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli - Cholera toxin B subunit vaccine in Egyptian adults  
AU Savarino S J (Reprint); Brown F M; Hall E; Bassily S; Youssef F; Wierzb T; Peruski L; ElMasry N A; Safwat M; Rao M; Jertborn M; Svennerholm A M; Lee Y J; Clemens J D  
CS USN, MED RES UNIT 3, PSC 452, BOX 127, FPO, AE 09835 (Reprint); USN, MED RES UNIT 3, CAIRO, EGYPT; EGYPTIAN MINIST HLTH, BANHA, EGYPT; NICHHD, NIH, BETHESDA, MD 20892; GOTHENBURG UNIV, GOTHENBURG, SWEDEN  
CYA USA; EGYPT; SWEDEN  
SO JOURNAL OF INFECTIOUS DISEASES, (MAR 1998) Vol. 177, No. 3, pp. 796-799. Publisher: UNIV CHICAGO PRESS, 5720 S WOODLAWN AVE, CHICAGO, IL 60637. ISSN: 0022-1899.  
DT Article; Journal  
FS LIFE; CLIN  
LA English  
REC Reference Count: 14

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*  
AB Enterotoxigenic Escherichia coli (**ETEC**) is the leading cause of bacterial diarrhea in young children in developing countries. The safety and immunogenicity of a killed, oral **ETEC vaccine** consisting of whole cells plus recombinantly produced cholera toxin B subunit (rCTB) was evaluated in Egypt, which is endemic for **ETEC** diarrhea. Seventy-four healthy Egyptian adults (21-45 years old) were randomized and received two doses of the **ETEC/rCTB vaccine** (E003) or placebo 2 weeks apart. The frequency of adverse events after either dose did not differ by treatment group, and no severe adverse events were reported. After vaccination, peripheral blood IgA B cell responses to CTB (100%) and to **vaccine** colonization factor antigens CFA/I (94%), **CS4** (100%), CS2 (81%), and CS1 (69%) were significantly higher than response rates for the placebo group. These favorable results in Egyptian adults indicate that the **ETEC/rCTB vaccine** is a promising candidate for evaluation in younger age groups in this setting.

IN Altboum Z; Levine M M; Barry E M  
PA (UYMA-N) UNIV MARYLAND BALTIMORE.  
PI WO 2001081582 A2 20011101 81p  
AI WO 2001-US12914 20010420  
PRAI US 2000-198686P 20000420  
DT Patent  
LA English  
OS 2002-049280 [06]  
AN AAM50343 Protein DGENE  
AB The present sequence is that of the tip associated protein CsaE of enterotoxigenic Escherichia coli (**ETEC**) strain E11881A. CsaE is encoded by the csaE gene (see AAI70763) of the E. coli E11881A csa operon. This operon includes 5 contiguous genes, csaA-csaE, which encode the synthesis of **ETEC-CS4** pili. It has been expressed in attenuated Shigella strain CVD1204 guaBA, constructing the Shigella expressing **CS4** fimbriae **vaccine** strain CVD1204 (pGA2-**CS4**). The CsaE protein has a calculated mol.wt. of 40102.4 and a theoretical pI of 8.74. It shows homology to similar proteins from other **ETEC** fimbriae. Recombinant CsaA-CsaE polypeptides are used in claimed immunogenic compositions to generate an immune response in a subject. These prevent **ETEC** colonisation, and hence protect against diarrhoea.

L9 ANSWER 18 OF 44 DGENE (C) 2002 THOMSON DERWENT  
 AN AAM50342 Protein DGENE  
 TI New nucleotide sequence, useful as immunogenic agent for generating immune response against recombinant product of the operon, comprises csa operon which encodes enterotoxigenic Escherichia coli-**CS4** pili  
 -  
 IN Altboum Z; Levine M M; Barry E M  
 PA (UYMA-N) UNIV MARYLAND BALTIMORE.  
 PI WO 2001081582 A2 20011101 81p  
 AI WO 2001-US12914 20010420  
 PRAI US 2000-198686P 20000420  
 DT Patent  
 LA English  
 OS 2002-049280 [06]  
 AN AAM50342 Protein DGENE  
 AB The present sequence is that of regulatory protein CsaD of enterotoxigenic Escherichia coli (**ETEC**) strain E11881A. CsaD is encoded by the disrupted csaD gene (see AAI70762) of the E. coli E11881A csa operon, and lacks the N-terminal 48 amino acid. The csa operon includes 5 contiguous genes, csaA-csaE, which encode the synthesis of **ETEC-CS4** pili. It has been expressed in attenuated Shigella strain CVD1204 guaBA, constructing the Shigella expressing **CS4** fimbriae vaccine strain CVD1204 (pGA2-**CS4**). Recombinant CsaA-CsaE polypeptides are used in claimed immunogenic compositions to generate an immune response in a subject. These prevent **ETEC** colonisation, and hence protect against diarrhoea.

L9 ANSWER 22 OF 44 DGENE (C) 2002 THOMSON DERWENT  
 AN AAW48316 peptide DGENE  
 TI Monoclonal antibody agglutinating Escherichia coli with **CS4** -CFA/I family protein - is useful in assays and for treatment or prophylaxis against illness arising from infection with E. coli bearing **CS4**-CFA/I family proteins  
 IN Cassels F; Lees A; Schuman R  
 PA (USSA) US DEPT OF THE ARMY.  
 (VIRI-N) VIRION SYSTEMS INC.  
 PI WO 9805687 A1 19980212 14p  
 AI WO 1997-US13477 19970801  
 PRAI US 1996-23075 19960802  
 DT Patent  
 LA English  
 OS 1998-145553 [13]  
 AN AAW48316 peptide DGENE  
 AB The present sequence represents an Escherichia coli family **CS4** -CFA/I **immunogen** consensus peptide. The present invention describes a new monoclonal antibody which binds exclusively and specifically to SAVALTYS, agglutinates bacteria bearing **CS4** -CFA/I family proteins and is produced by hybridoma 96-109FE8 IH11. The monoclonal antibody can agglutinate members of the Escherichia coli family CSA-CFA/I, since it was raised to a consensus peptide known to raise antibodies against proteins of all the CSA-CFA/I family. E. coli causing diarrhoea are grouped into five classes, of which enterotoxigenic (**ETEC**), to which the **CS4**-CFA/I family belong, are the most common and pose the greatest risk to travellers. **ETEC** E. coli cause high infant mortality and illness in adult travellers in developing countries. The antibody is useful in assays to detect/identify organisms bearing **CS4**-CFA family proteins, by contacting cultures of organisms for sufficient time for interaction, and

determining whether a **CS4**-CFA/I family protein/antibody complex has formed. It can be included in compositions with a carrier appropriate for application to bacteria-containing growth media, optionally with a tag e.g. a fluorescing agent or colorometric tag, to assist identification of the complex. It can also be included in compositions with pharmaceutically acceptable carriers, especially saline, useful for treating or prophylaxing against illness arising from infection with bacteria bearing **CS4**-CFA/I family proteins

## WEST Search History

DATE: Thursday, July 18, 2002

**Set Name** **Query**  
side by side

**Hit Count** **Set Name**  
result set

*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR*

L3 CS4 same (vaccine immunogen)

9 L3

L2 L1 and @ad<20000420

19 L2

L1 (CS4 or (coli adj surface adj antigen adj 4)) and (immunogen\$4  
vaccine)

24 L1

END OF SEARCH HISTORY